-
Antibody Combination Shown to Suppress HIV
Results from a small-scale clinical trial show a combination of antibodies can suppress the HIV virus for many weeks after stopping antiretroviral therapy.
-
How Advancing Technology Can Alleviate Employee Stress
Thanks to advancing technology, it’s becoming easier to keep workers stress levels in check, which is good for them, and good for their business.
-
$29.5M Funding Raised for Sinus Drug Delivery Company
A company developing a drug delivery technology to treat chronic sinus conditions is raising $29.5 million in its second venture financing round.
-
Genome Centers Named for Precision Medicine Program
Three medical research centers in the U.S. will begin analyzing the DNA in specimen samples from participants in a large-scale precision medicine initiative conducted by National Institutes of Health.
-
Product Packaging — Why It Matters
Your product packaging is so much more than just a practical feature – it is also an invaluable marketing tool.
-
Umbilical Cord Grafts Shown to Heal Foot Ulcers
Results from a clinical trial show skin grafts made from dehydrated human umbilical cord tissue heal more diabetic foot ulcers than alginate dressings, a common treatment for the condition.
-
Synthetic Antibody Neutralizing Gluten in Development
An academic-business team is developing a synthetic antibody to prevent gluten found in some grains from affecting the intestines of people with celiac disease, an intolerance of gluten.
-
Next Steps For Your Business — The Options To Consider
If you have your business and it has moved on from those early days, you may be wondering what is the next step for you and your company?
-
Algorithms Advance Assistive Control for Spinal Cord Injury
A system to control movements of an assistive sleeve is shown in lab tests to enable a person with no use of his arms and legs due to spinal cord injury to accurately grasp and release objects.
-
Liquid Biopsy for Solid Tumors Now Available
A test that inspects a patient’s blood sample for characteristic indicators of solid-tumor cancer, and can be part of a comprehensive precision analytics program, is now on the market.